Search
Opelconazole
go.drugbank.com/drugs/DB18251InvestigationalCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP3A InducersrAAV9-hNAGLU
go.drugbank.com/drugs/DB18415ExperimentalrAAV9-hNAGLU consists of a recombinant AAV9 expressing human alpha-N-acetylglucosaminidase.
CC-90001
go.drugbank.com/drugs/DB18445InvestigationalCategories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsAPPD
go.drugbank.com/drugs/DB18603ExperimentalCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesP-42 peptide
go.drugbank.com/drugs/DB18610ExperimentalP-42 peptide is a synthetic 23 amino acid peptide AASSGVSTPGSAGHDIITEQPRS derived from the Huntingtin protein
Divesiran
go.drugbank.com/drugs/DB18646InvestigationalDivesiran is a synthetic double-stranded siRNA oligonucleotide directed against TMPRSS6 mRNA and covalently linked to a ligand containing 3 N-acetylgalactosamine residues.
Palopegteriparatide
go.drugbank.com/drugs/DB18676ApprovedInvestigational[L51134] PTH(1-34) contains the N-terminal part of the endogenous PTH molecule.
Synonyms: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34, Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-L-seryl-L-valyl-L-seryl-L-α-glutamyl-L-isoleOlezarsen
go.drugbank.com/drugs/DB18728ApprovedInvestigational[A264888,A264893] Olezarsen is conjugated to a ligand containing three N-acetyl-galactosamine (GalNAc) residues to enable its delivery to hepatocytes.
Synonyms: ALL-P-AMBO-5'-O-(((6-(5-((TRIS(3-(6-(2-ACETAMIDO-2-DEOXY-.BETA., -D-GALACTOPYRANOSYLOXY)HEXYLAMINO)-3-OXOPROPOXYMETHYL))METHYL)AMINO-5-OXOPENTANAMIDO)HEXYL))PHOSPHO)-2'-O-(2-METHOXYETHYL)-P-THIOADENYLYL-(3'-O->5'-O)-2'-O-(2-METHOXYETHYL)-P-THIOGUANYLYL-(3Enavogliflozin
go.drugbank.com/drugs/DB18970InvestigationalEnavogliflozin is under investigation in clinical trial NCT06399835 (Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPlozasiran
go.drugbank.com/drugs/DB18997ApprovedInvestigationalPlozasiran contains a covalently linked ligand containing three N-acetylgalactosamine (GalNAc) residues to facilitate delivery to hepatocytes where it works to reduce triglyceride levels.